FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: The FDA's approval of this gene therapy could significantly impact Ohio, where sickle cell disease is a prevalent health concern, particularly within diverse communities. This treatment offers a new option for young patients experiencing severe forms of the disease.

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).